1. Adams DM, Hammill AM, Mobberley-Schuman PS, Trenor CC, 3rd. Comment On: Steroid-Resistant Kaposiform Hemangioendothelioma: A Retrospective Study of 37 Patients Treated with Vincristine and Long-Term Follow-Up. Pediatr Blood Cancer. 2015; 62:2056.
  2. Adams DM, Trenor CC, 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatr. 2016; 137:e20153257.
  3. Adams GN, Rosenfeldt L, Frederick M, Miller W, Waltz D, Kombrinck K, McElhinney KE, Flick MJ, Monia BP, Revenko AS, Palumbo JS. Colon Cancer Growth and Dissemination Relies Upon Thrombin, Stromal Par-1, and Fibrinogen. Cancer Research. 2015; 75:4235-43.
  4. Alsaied T, Alsidawi S, Allen CC, Faircloth J, Palumbo JS, Veldtman GR. Strategies for Thromboprophylaxis in Fontan Circulation: A Meta-Analysis. Heart. 2015; 101:1731-7.
  5. Anyanwu J, Williams O, Sautter C, Kasirye P, Hume H, Opoka R, Latham T, Ndugwa C, Ware R, John C. Novel Use of Hydroxyurea in an African Region with Malaria: Protocol for a Randomized Controlled Clinical Trial. pmc/PMC4937184. JMIR Research Protocols. 2016; 5:e110.
  6. Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg A, Shaw MA, Rizvi T, Wansapura J, Degen JL, Malik P. Genetic Diminution of Circulating Prothrombin Ameliorates Multiorgan Pathologies in Sickle Cell Disease Mice. Blood. 2015; 126:1844-55.
  7. Burkes SA, Adams DM, Hammill AM, Chute C, Eaton KP, Welge JA, Wickett RR, Visscher MO. Skin Imaging Modalities Quantify Progression and Stage of Infantile Haemangiomas. Br J Dermatol. 2015; 173:838-41.
  8. Burkes SA, Patel M, Adams DM, Hammill AM, Eaton KP, Randall Wickett R, Visscher MO. Infantile Hemangioma Status by Dynamic Infrared Thermography: A Preliminary Study. Int J Dermatol. 2016; 55:e522-32.
  9. Chonat S, Chandrakasan S, Kalinyak K, Ingala D, Gruppo R, Kalfa T. Atypical Haemolytic Uraemic Syndrome in a Patient with Sickle Cell Disease, Successfully Treated with Eculizumab. Br J Haematol. 2016.
  10. Cohen R, Smith E, Arbabi S, Quinn C, Franco R. Do Red Blood Cell Indices Explain Racial Differences in the Relationship between Hemoglobin A1c and Blood Glucose? J Pediatr. 2016; 176:7-9.
  11. Comi AM, Sahin M, Hammill A, Kaplan EH, Juhasz C, North P, Ball KL, Levin AV, Cohen B, Morris J, Lo W, Roach ES, Sturge-Weber Syndrome Research Workshop. Leveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research. Pediatr Neurol. 2016; 58:12-24.
  12. Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a Pharmacokinetic-Guided Dose Individualization Strategy for Hydroxyurea Treatment in Children with Sickle Cell Anaemia. Br J Clin Pharmacol. 2016; 81:742-52.
  13. Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Jason Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter SD, Sharma M, Davidoff AM, Nottage K, Bernabe K, et al. Hematologic Outcomes after Total Splenectomy and Partial Splenectomy for Congenital Hemolytic Anemia. J Pediatr Surg. 2016; 51:122-7.
  14. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, et al. Clinical and Laboratory Variability in a Cohort of Patients Diagnosed with Type 1 Vwd in the United States. Blood. 2016; 127:2481-8.
  15. Gaballah M, Shi J, Kukreja K, Raffini L, Tarango C, Keller M, Krishnamurthy G, Racadio J, Patel M, Cahill AM. Endovascular Thrombolysis in the Management of Iliofemoral Thrombosis in Children: A Multi-Institutional Experience. J Vasc Interv Radiol. 2016; 27:524-30.
  16. Giger KM, Kalfa TA. Phylogenetic and Ontogenetic View of Erythroblastic Islands. Biomed Res Int. 2015; 2015:873628.
  17. Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S, Kids Dott Trial Investigators. Multicenter Randomized Controlled Trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-Dott Trial): Pilot/Feasibility Phase Findings. J Thromb Haemost. 2015; 13:1597-605.
  18. Hankins JS, McCarville MB, Rankine-Mullings A, Reid ME, Lobo CL, Moura PG, Ali S, Soares DP, Aldred K, Jay DW, Aygun B, Bennett J, Kang G, Goldsmith JC, Smeltzer MP, Boyett JM, Ware RE. Prevention of Conversion to Abnormal Transcranial Doppler with Hydroxyurea in Sickle Cell Anemia: A Phase Iii International Randomized Clinical Trial. Am J Hematol. 2015; 90:1099-105.
  19. Huang Y, Shaw M, Warmin M, Mullins E, Ayres N. Blood Compatibility of Heparin-Inspired, Lactose Containing, Polyureas Depends on the Chemistry of the Polymer Backbone. Polym Chem. 2016; 7:3897-905.
  20. Konstantinidis DG, Giger KM, Risinger M, Pushkaran S, Zhou P, Dexheimer P, Yerneni S, Andreassen P, Klingmuller U, Palis J, Zheng Y, Kalfa TA. Cytokinesis Failure in Rhoa-Deficient Mouse Erythroblasts Involves Actomyosin and Midbody Dysregulation and Triggers P53 Activation. Blood. 2015; 126:1473-82.
  21. Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M, Investigators of the Leopold Kids Trial. Bay 81-8973 Safety and Efficacy for Prophylaxis and Treatment of Bleeds in Previously Treated Children with Severe Haemophilia A: Results of the Leopold Kids Trial. Haemophilia. 2016; 22:354-60.
  22. Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, et al. Effects of Hydroxyurea Treatment for Patients with Hemoglobin Sc Disease. Am J Hematol. 2016; 91:238-42.
  23. McGann P. Time to Invest in Sickle Cell Anemia as a Global Health Priority. Pediatr Ann. 2016; 137:e 20160348.
  24. McGann P. Improving Survival for Children with Sickle Cell Disease: Newborn Screening Is Only the First Step. Paediatr Int Child Health. 2015; 35:285-86.
  25. McGann P, Ware R. Hydroxyurea Therapy for Sickle Cell Anemia. Expert Opin Drug Saf. 2015; 14:1749-58.
  26. McGann PT. Hydroxyurea for Abnormal Tcds: Safe to Switch? Blood. 2016; 127:1738-40.
  27. McGann PT, Grosse SD, Santos B, de Oliveira V, Bernardino L, Kassebaum NJ, Ware RE, Airewele GE. A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola. J Pediatr. 2015; 167:1314-9.
  28. McGann PT, Schaefer BA, Paniagua M, Howard TA, Ware RE. Characteristics of a Rapid, Point-of-Care Lateral Flow Immunoassay for the Diagnosis of Sickle Cell Disease. Am J Hematol. 2016; 91:205-10.
  29. McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T, Aygun B, Obaro SK, Olupot-Olupot P, Williams TN, Odame I, Ware RE, Reach Investigators. Hydroxyurea Therapy for Children with Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the Reach Trial. Pediatr Blood Cancer. 2016; 63:98-104.
  30. McGann PT, Tyburski EA, de Oliveira V, Santos B, Ware RE, Lam WA. An Accurate and Inexpensive Color-Based Assay for Detecting Severe Anemia in a Limited-Resource Setting. Am J Hematol. 2015; 90:1122-7.
  31. Mullins TL, Miller RJ, Mullins ES. Evaluation and Management of Adolescents with Abnormal Uterine Bleeding. Pediatr Ann. 2015; 44:e218-22.
  32. Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, Wellendorf AM, Valencia CA, Paddison PJ, Horwitz MS, Grimes HL, Lutzko C, Cancelas JA. Pathogenesis of Elane-Mutant Severe Neutropenia Revealed by Induced Pluripotent Stem Cells. J Clin Invest. 2015; 125:3103-16.
  33. Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of Sickle Cell Trait and Disease in the Uganda Sickle Surveillance Study (Us3): A Cross-Sectional Study. Lancet Glob Health. 2016; 4:e195-200.
  34. Niss O, Quinn CT, Lane A, Daily J, Khoury PR, Bakeer N, Kimball TR, Towbin JA, Malik P, Taylor MD. Cardiomyopathy with Restrictive Physiology in Sickle Cell Disease. JACC Cardiovasc Imaging. 2016; 9:243-52.
  35. Prasad J, Gorkun O, Raghu H, Thornton S, Mullins E, Palumbo J, Ko Y-P, Höök M, David T, Coughlin S. Mice Expressing a Mutant Form of Fibrinogen That Cannot Support Fibrin Formation Exhibit Compromised Antimicrobial Host Defense. Blood. 2015; 126:2047-58.
  36. Quinn C. Do Not Leave for Tomorrow What You Can Do Today. Pediatr Blood Cancer. 2015; 62:1879-80.
  37. Quinn CT. Minireview: Clinical Severity in Sickle Cell Disease: The Challenges of Definition and Prognostication. Exp Biol Med (Maywood). 2016; 241:679-88.
  38. Quinn CT, St Pierre TG. Mri Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer. 2016; 63:773-80.
  39. Rivera CP, Veneziani A, Ware RE, Platt MO. Original Research: Sickle Cell Anemia and Pediatric Strokes: Computational Fluid Dynamics Analysis in the Middle Cerebral Artery. Exp Biol Med (Maywood). 2016; 241:755-65.
  40. Salloum R, Fox CE, Alvarez-Allende CR, Hammill AM, Dasgupta R, Dickie BH, Mobberley-Schuman P, Wentzel MS, Chute C, Kaul A, Patel M, Merrow AC, Gupta A, Whitworth JR, Adams DM. Response of Blue Rubber Bleb Nevus Syndrome to Sirolimus Treatment. Pediatr Blood Cancer. 2016; 63:1911-4.
  41. Serai S, Fleck R, Quinn C, Zhang B, Podberesky D. Retrospective Comparison of Gradient Recalled Echo R2*and Spin-Echo R2 Magnetic Resonance Analysis Methods for Estimating Liver Iron Content in Children and Adolescents. Pediatr Radiol. 2015; 45:1629-34.
  42. Unruh D, Srinivasan R, Benson T, Haigh S, Coyle D, Batra N, Keil R, Sturm R, Blanco V, Palascak M, Franco RS, Tong W, Chatterjee T, Hui DY, Davidson WS, Aronow BJ, Kalfa T, Manka D, Peairs A, Blomkalns A, et al. Red Blood Cell Dysfunction Induced by High-Fat Diet: Potential Implications for Obesity-Related Atherosclerosis. Circulation. 2015; 132:1898-908.
  43. Ware RE. Optimizing Hydroxyurea Therapy for Sickle Cell Anemia. Hematology Am Soc Hematol Educ Program. 2015; 2015:436-43.
  44. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, et al. Hydroxycarbamide Versus Chronic Transfusion for Maintenance of Transcranial Doppler Flow Velocities in Children with Sickle Cell Anaemia-Tcd with Transfusions Changing to Hydroxyurea (Twitch): A Multicentre, Open-Label, Phase 3, Non-Inferiority Trial. Lancet. 2016; 387:661-70.
  45. Wood JC, Cohen AR, Pressel SL, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Schultz WH, Davis BR, Ware RE, TWiTCH Investigators. Organ Iron Accumulation in Chronically Transfused Children with Sickle Cell Anaemia: Baseline Results from the Twitch Trial. Br J Haematol. 2016; 172:122-30.
  46. Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE, TWiTCH Investigators. Liver Iron Concentration Measurements by Mri in Chronically Transfused Children with Sickle Cell Anemia: Baseline Results from the Twitch Trial. Am J Hematol. 2015; 90:806-10.